August 2015 Vol 8, Special Issue: Payers' Perspectives in Oncology

Value-Based Healthcare Delivery: The Agenda for Oncology

Emerging Therapies

Nivolumab Beats Docetaxel as Second-Line Therapy for Patients with NSCLC

Searching for the Tipping Point in Drug Pricing

Caroline Helwick

Emerging Therapies

Oncology Pipeline Full, and Not Just with Immunotherapies

Caroline Helwick, Wayne Kuznar

Aetna Examines Impact of Site of Service on Chemotherapy Cost

Caroline Helwick

Treating with Checkpoint Inhibitors—Figure $1 Million per Patient

Researchers Dissect the Cost of Targeted Agents

Caroline Helwick

Bevacizumab Wins Cost-Effectiveness Contest in First-Line Metastatic Colorectal Cancer

Caroline Helwick

Will Necitumumab Be Cost-Effective?

Caroline Helwick

1
2
3
4

Page 1 of 4
Results 1 - 10 of 37

SUBSCRIBE

© Amplity Health. All rights reserved.

Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive:

AHDB Print Edition

AHDB Weekly e‑Newsletter

I have reviewed and consent to the terms of AHDB's Privacy Policy, and AHDB has my permission to retain my information in its database, and to forward pertinent communications to me.